Utility of PharmacoGenomics for Reducing Adverse Drug Effects

Inclusion Criteria:

- Subject plans to undergo current index PGx testing at the time of enrollment or
underwent current index PGx testing within the prior 1-year period, for genes known
to influence metabolism of at least one target drug

- Subject is aged ≥18 years

- Subject is able and willing to provide written informed consent

- Subject reveals a history of at least one TDAE or an inadequate therapeutic effect
from a target drug over the 12-month period preceding expected receipt of PGx test
results

- Subject is not taking an investigational medication or in an interventional trial
that would interfere with participation in the registry

Exclusion Criteria:

- Subject is currently hospitalized

- Subject's medical and medication history is unavailable over the 90-day periods
preceding and following the receipt of pharmacogenomic test results

- Subject is unable to provide an accurate history due to mental incapacity

- Subject is known to have undergone prior pharmacogenomic testing (exclusive of the
current index PGx testing) for genes specific to the target drugs within the 2-year
period preceding enrollment and these results have been previously evaluated